| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Longeveron Inc. | Chief Executive Officer | Class A Common Stock | 294,467 | $156,067 | $0.5300 | 02 Mar 2026 | Direct |
| NRX Pharmaceuticals, Inc. | CHIEF EXECUTIVE OFFICER, Director | Common Stock, par value $0.001 per share | 50,000 | $15,995 | $0.3199 | 16 Dec 2022 | Direct |
| Longeveron Inc. | Chief Executive Officer | Stock Option (right to buy) | 200,000 | 02 Mar 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LGVN | Longeveron Inc. | 02 Mar 2026 | 4 | $0 | 4 | Chief Executive Officer | 13 Mar 2026, 20:59 |
| LGVN | Longeveron Inc. | 11 Feb 2026 | 0 | $0 | 3 | Chief Executive Officer | 13 Mar 2026, 20:58 |
| NRXP | NRX Pharmaceuticals, Inc. | 16 Dec 2022 | 1 | +$58,500 | 4 | CHIEF EXECUTIVE OFFICER, Director | 19 Dec 2022, 06:14 |
| NRXP | NRX Pharmaceuticals, Inc. | 12 Jul 2022 | 0 | $0 | 3 | Chief Executive Officer, Director | 22 Jul 2022, 16:27 |